Royalty Pharma plc (RPRX-Q)
NASDAQ:RPRX
32.45
0.14
(0.43%) 1d
Financials
Technical Analysis
Buy, Sell or Hold?
Related posts
Nervous markets await Nvidia
This summary was created by AI, based on 3 opinions in the last 12 months.
Royalty Pharma plc (RPRX) is gaining attention as a top Pick due to its strategic investments in jointly developed royalty products with major pharmaceutical companies. The company has a diverse portfolio of 35 products and is actively developing new projects. Analysts praise its strong financial performance, citing metrics such as a 12% to 24% Return on Equity (ROE) and a reasonable earnings multiple ranging from 8x to 17x depending on the source. The company recently realized a significant return on a past investment, providing funds for debt reduction and further development, which enhances its financial stability. With a stable yield ranging from 2.6% to 3.2%, RPRX presents a solid investment opportunity with notable upside potential.
We reiterate RPRX as a TOP PICK. This unique pharma company has investments in 35 jointly developed royalty products, with the largest pharma companies and has several new joint products in development. It trades at 17x earnings, 2.1x book and supports a 12% ROE. We recommend trailing up the stop (from $26) to $29, looking to achieve $41 — upside potential of 25%. Yield 2.6%
(Analysts’ price target is $41.00)We reiterate RPRX as a TOP PICK. The company is the largest holder of pharma based royalties, providing late stage funding for forward cash royalties. The company just monetized a recent investment that netted $230 million -- a 76% return on investment -- allowing for a pay down in debt, continuation in share buy backs, and further product development. The company trades at 8x earnings, 1.8x book and supports a ROE of 24%. We recommend trailing up the stop (from $22) to $26, looking to achieve $40 -- upside potential of 25%. Yield 2.6%
RPRX partners with pharma companies like Bristol-Myers to help fund development in exchange for collecting royalties. It pays a good dividend, backed by a payout ratio under 33% of cash flow. It trades at 10x earnings, under 2x book and supports a 17% ROE. Its portfolio grew by 15% this year. We recommend setting a stop-loss at $22, looking to achieve $33 -- upside potential of 28%. Yield 3.2%
(Analysts’ price target is $41.53)- «
- ‹
- 1
- ›
- »
Royalty Pharma plc(RPRX-Q) Rating
Ranking : 1 out of 5
Bullish - Buy Signals / Votes : 0
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 0
Royalty Pharma plc(RPRX-Q) Frequently Asked Questions
What is Royalty Pharma plc stock symbol?
Royalty Pharma plc is a American stock, trading under the symbol RPRX-Q on the NASDAQ (RPRX). It is usually referred to as NASDAQ:RPRX or RPRX-Q
Is Royalty Pharma plc a buy or a sell?
In the last year, there was no coverage of Royalty Pharma plc published on Stockchase.
Is Royalty Pharma plc a good investment or a top pick?
Royalty Pharma plc was recommended as a Top Pick by on . Read the latest stock experts ratings for Royalty Pharma plc.
Why is Royalty Pharma plc stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Royalty Pharma plc worth watching?
0 stock analysts on Stockchase covered Royalty Pharma plc In the last year. It is a trending stock that is worth watching.
What is Royalty Pharma plc stock price?
On 2025-05-23, Royalty Pharma plc (RPRX-Q) stock closed at a price of $32.45.
Following recently reported earnings, we reiterate RPRX as a TOP PICK. Their drug portfolio royalty receipts are showing steady growth - up another 12% this year. Management sees good progress on new projects, including a recent announcement of a partnership with Biogen. It trades at 17x earnings, 2.1x book, and supports a 12% ROE. We continue to recommend a stop at $29, looking to achieve $40 -- upside potential of 21%. Yield 2.5%
(Analysts’ price target is $39.80)